Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.68 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 4/20 | 0.35 |
| ▸ | GABRD | O14764 | 4/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.35 |
| ▸ | GABRE | P78334 | 4/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL197140 | 1.00 | SLC7A5 (0.68) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL3081722 | 1.00 | SLC7A5 (0.68) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL4588481 | 1.00 | SLC7A5 (0.68) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL5966382 | 1.00 | SLC7A5 (0.68) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL18927234 | 0.92 | SLC7A5 (0.65) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL5065202 | 0.85 | — | — | |
| SCHEMBL13502414 | 0.82 | SLC7A5 (0.60) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL1813972 | 0.81 | SLC7A5 (1.00) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL43678 | 0.81 | — | — | |
| Valine SCHEMBL8516 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119592528-A | L-amino acid ligase and application thereof in catalytic synthesis of L-valine dipeptide and derivatives thereof | 上海合全药物研发有限公司 | 2025-03-11 | — | — | CN | claimed |
| CN-117881394-A | Pharmaceutical composition and oral dosage form of ketamine derivative | 凯瑞康宁生物工程（武汉）有限公司 | 2024-04-12 | — | — | CN | claimed |
| CN-111836798-B | Prodrugs of ketamine, compositions and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2022-04-15 | — | — | CN | claimed |
| CN-112135812-A | Ketamine derivatives and pharmaceutical compositions thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2020-12-25 | — | — | CN | claimed |
| US-20250320233-A1 | ARGINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO LTD (KR) | 2025-10-16 | — | — | US | disclosed |
| EP-4538278-A1 | ARGINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Daewoong Pharmaceutical Co., Ltd. (KR) | 2025-04-16 | — | — | EP | disclosed |
| US-20250099424-A1 | Nitrile-Containing Antiviral Compounds | PFIZER INC. (US) | 2025-03-27 | — | — | US | disclosed |
| US-20250084088-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2025-03-13 | — | — | US | disclosed |
| CN-119592528-A | L-amino acid ligase and application thereof in catalytic synthesis of L-valine dipeptide and derivatives thereof | 上海合全药物研发有限公司 | 2025-03-11 | — | — | CN | disclosed |
| WO-2025049493-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| EP-4516301-A2 | NITRILE-CONTAINING COMPOUNDS FOR USE AS MEDICAMENTS | Pfizer Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| CN-119213001-A | Arginase inhibitors and pharmaceutical compositions comprising same | 株式会社大熊制药 | 2024-12-27 | — | — | CN | disclosed |
| EP-1578910-A2 | NITRILASES | DIVERSA CORPORATION (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1576108-A2 | NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | DIVERSA CORPORATION (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20040014195-A1 | Nitrilases, nucleic acids encoding them and methods for making and using them | DIVERSA CORPORATION (US) | 2004-01-22 | — | — | US | disclosed |
| US-20040002147-A1 | Nitrilases | DIVERSA CORPORATION | 2004-01-01 | — | — | US | disclosed |
| WO-2003097810-A2 | NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | DIVERSA CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
| US-20030124698-A1 | Which stereoselectively hydrolyze nitrites or cyanohydrins into acids and ammonia | DIVERSA CORPORATION | 2003-07-03 | — | — | US | disclosed |
| WO-2003000840-A2 | NITRILASES | DIVERSA CORPORATION (US) | 2003-01-03 | — | — | WO | disclosed |
| US-5696230-A | ACYCLIC OLIGOPEPTIDE HAVING CONSTRAINED BACKBONE CONFORMATION AND SPASMOGENIC, PLATELET AGGREGATORY, NEUTROPHIL POLARIZATION AND/OR NEUTROPHIL ENZYME RELEASE ACTIVITY | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1997-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014195-A1 | Nitrilases, nucleic acids encoding them and methods for making and using them | RNGTT, NSUN2, NSUN3 | SLC7A5 1798/4885SLC1A3 1001/4885SLC1A2 1013/4885 |
| US-20040002147-A1 | Nitrilases | RNGTT, DNTT, NOP2 | SLC7A5 1746/4885SLC1A3 1217/4885SLC1A2 999/4885 |
| US-20250320233-A1 | ARGINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ARG1, ARG2, PRMT1 | SLC7A5 1030/4885SLC1A3 1134/4885SLC1A2 1462/4885 |
| US-20030124698-A1 | Which stereoselectively hydrolyze nitrites or cyanohydrins into acids and ammonia | NIT2, DNPH1, ASNS | SLC7A5 1527/4885SLC1A3 1115/4885SLC1A2 1261/4885 |
| US-20250099424-A1 | Nitrile-Containing Antiviral Compounds | ACE2, NOS2, EIF2AK2 | SLC7A5 3787/4885SLC1A3 4168/4885SLC1A2 3950/4885 |
| US-20250084088-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | EIF2AK2, MAVS, ZC3HAV1 | SLC7A5 3029/4885SLC1A3 4329/4885SLC1A2 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.